Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells

[1]  B. Aggarwal,et al.  Targeting constitutive and interleukin‐6‐inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane) , 2006, International journal of cancer.

[2]  W. Young,et al.  Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. , 2006, Biochemical and biophysical research communications.

[3]  B. Wollenberg,et al.  Secretion of tumor-promoting and immune suppressive cytokines by cell lines of head and neck squamous cell carcinoma. , 2006, In vivo.

[4]  G. Gallagher,et al.  Interleukin-6 enhances the induction of human lymphokine-activated killer cells , 2005, Cancer Immunology, Immunotherapy.

[5]  S. Takashiba,et al.  High Glucose Enhances Interleukin-6-induced Vascular Endothelial Growth Factor 165 Expression via Activation of Gp130-mediated p44/42 MAPK-CCAAT/Enhancer Binding Protein Signaling in Gingival Fibroblasts* , 2004, Journal of Biological Chemistry.

[6]  G. Dyckhoff,et al.  Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck , 2003, International journal of cancer.

[7]  K. Song,et al.  Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. , 2003, Cancer Research.

[8]  M. Waters,et al.  Suppressor of cytokine signalling gene expression is elevated in breast carcinoma , 2003, British Journal of Cancer.

[9]  J. S. Gutkind,et al.  Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. , 2003, Cancer research.

[10]  J. D. Vos,et al.  A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells , 2003, Oncogene.

[11]  R. Vessella,et al.  Elevation of cytokine levels in cachectic patients with prostate carcinoma , 2003, Cancer.

[12]  Razelle Kurzrock,et al.  Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. , 2002, Cancer research.

[13]  K. Pile,et al.  Serum interleukin-6 and thyroid hormones in rheumatoid arthritis. , 2001, Metabolism: clinical and experimental.

[14]  N. Hynes,et al.  Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. , 2001, Cancer research.

[15]  J. Soria,et al.  Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes. , 2000, Cytokine.

[16]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[17]  E. Vellenga,et al.  Regulation of spontaneous and TNF/IFN‐induced IL‐6 expression in two human ovarian‐carcinoma cell lines , 1999, International journal of cancer.

[18]  C. Smith,et al.  Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  H. Saito,et al.  Granulocyte‐colony‐stimulating factor enhances invasive potential of human head‐and‐neck‐carcinoma cell lines , 1999, International journal of cancer.

[20]  G. Clayman,et al.  Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. , 1998, Cancer research.

[21]  H. Kung,et al.  Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells , 1998, Nature.

[22]  H. Nishino,et al.  The effect of interleukin-6 on enhancing the invasiveness of head and neck cancer cells in vitro , 1998, European Archives of Oto-Rhino-Laryngology.

[23]  S. Harroch,et al.  Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells , 1997, Oncogene.

[24]  F. Kikkawa,et al.  Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. , 1997, Anticancer research.

[25]  R. Oyasu,et al.  Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. , 1997, Cancer research.

[26]  Y. Ohsugi,et al.  IL-6-soluble IL-6 receptor complex inhibits the proliferation of dermal fibroblasts. , 1996, International journal of immunopharmacology.

[27]  B. Klein,et al.  Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. , 1995, Blood.

[28]  E. Gertz,et al.  Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. , 1995, Cancer research.

[29]  K. Ohta,et al.  Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. , 1993, Cancer research.

[30]  E. Heyderman,et al.  Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. , 1993, Gynecologic oncology.

[31]  D. Kreutzer,et al.  Cytokine expression by head and neck squamous cell carcinomas. , 1992, American journal of surgery.

[32]  J. Blay,et al.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. , 1992, Cancer research.

[33]  M. Kuwano,et al.  The response to epidermal growth factor of human maxillary tumor cells in terms of tumor growth, invasion and expression of proteinase inhibitors , 1991, International journal of cancer.

[34]  M. Nakajima,et al.  Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  K. Matsumoto,et al.  Interleukin 6 and expression of its receptor on epidermal keratinocytes. , 1990, Cytokine.

[36]  D. Welch.  Transforming growth factor β stimulates mamary adenocarcinoma cell invasion and metastasis potential , 1990 .

[37]  L. G. Thijs,et al.  Increased plasma levels of interleukin-6 in sepsis [see comments] , 1989 .

[38]  T. Kupper,et al.  Synergistic interactions of IL-1 and IL-6 in T cell activation. Mitogen but not antigen receptor-induced proliferation of a cloned T helper cell line is enhanced by exogenous IL-6. , 1989, Journal of immunology.

[39]  T. Kishimoto,et al.  The biology of interleukin-6. , 1989, Blood.

[40]  L A Aarden,et al.  Increased plasma levels of interleukin-6 in sepsis. , 1989, Blood.

[41]  T. Kishimoto,et al.  T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. , 1981, Journal of immunology.